Radiotherapy is the best treatment method in post transplant lymphoproliferative disorders localizing in brain: A review of the literature

Annals of Transplantation

Volumn 16, Issue 4, 2011, Pages 126-133

  Izadi, Morteza ^a   Fazel, Mozhgan ^b   Saadat, Seyed Hasan ^a   Taheri, Saeed ^c  

^a BAQIYATALLAH UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b International Travel Medicine Center of Iran   (Iran)

^c Dr Taheri Medical Research Group   (Iran)

Author keywords

Brain; Central nervous system; PTLD; Radiotherapy; Treatment strategies

Indexed keywords

ALLOTRANSPLANTATION; ARTICLE; CENTRAL NERVOUS SYSTEM; HUMAN; LYMPHOPROLIFERATIVE DISEASE; POST TRANSPLANT LYMPHOPROLIFERATIVE DISORDER; RADIOSENSITIZATION; SURVIVAL; TREATMENT OUTCOME; TREATMENT PLANNING;

EID: 84855475171     PISSN: 14259524     EISSN: None     Source Type: Journal    
DOI: 10.12659/AOT.882230     Document Type: Article

References (57)

1. Penn I, Hammond W, Brettschneider L, Starzl TE: Malignant lymphomas in transplantation patients. Transplant Proc, 1969; 1: 106-12
2. Pourfarziani V, Taheri S, Lessan-Pezeshki M et al: Lymphoma after living donor kidney transplantation: an Iranian multicenter experience. Int Urol Nephrol, 2008; 40(4): 1089-94
3. Izadi M, Taheri S: Significance of in situ hybridization results for EBV-encoded RNA in post-transplantation lymphoproliferative disorder setting: Report from the PTLD.Int Survey. Ann Transplant, 2010; 15(4): 102-9
4. Izadi M, Taheri S: Features, predictors and prognosis of lymphoproliferative disorders post-liver transplantation regarding disease presentation time: Report from the PTLD.Int. survey. Ann Transplant, 2011; 16(1): 39-47
5. Schenker P, Ozturk A, Vonend O et al: Singledose thymoglobulin induction in living-donor renal transplantation. Ann Transplant, 2011; 16(2): 50-58
6. Watorek E, Boratynska M, Smolska D et al: Malignancy after renal transplantation in the new era of immunosuppression. Ann Transplant, 2011; 16(2): 14-18
7. Khedmat H, Taheri S: Post-transplantation lymphoproliferative disorders localizing in the adenotonsillar region: report from the PTLD.Int survey. Ann Transplant, 2011; 16(1): 109-16
8. Khedmat H, Taheri S: Characteristics and prognosis of post-transplant lymphoproliferative disorders within renal allograft: Report from the PTLD.Int. Survey. Ann Transplant, 2010; 15(3): 80-86
9. Khedmat H, Taheri S: Late onset post transplantation lymphoproliferative disorders: analysis of international data from 5 studies. Ann Transplant, 2009; 14(4): 80-85
10. Khedmat H, Taheri S: Early onset post transplantation lymphoproliferative disorders: analysis of international data from 5 studies. Ann Transplant, 2009; 14(3): 74-77
11. Hanto DW, Gajl-Peczalska KJ, Frizzera G et al: Epstein- Barr virus (EBV) induced polyclonal and monoclonal B-cell lymphoproliferative diseases occurring after renal transplantation. Ann Surg, 1983; 198: 356-69
12. Cleary ML, Sklar J: Lymphoproliferative disorders in cardiac transplant recipients are multiclonal lymphomas. Lancet, 1984; 2: 489-93
13. Pitchenik AE, Fischl MA, Walls KW: Evaluation of cerebral-mass lesions in acquired immunodeficiency syndrome. N Engl J Med, 1983; 308: 1099
14. Shapiro R, Nalesnik M, McCauley J et al: Posttransplant lymphoproliferative disorders in adult and pediatric renal transplant patients receiving tacrolimus-based immunosuppression. Transplantation, 1999; 68: 1851
15. Cox KL, Lawrence-Miyasaki LS, Garcia-Kennedy R et al: An increased incidence of Epstein-Barr virus infection and lymphoproliferative disorder in young children on FK 506 after liver transplantation. Transplantation 1995; 27: 524
16. Khedmat H, Alavian SM, Taheri S: Significance of Epstein-Barr virus infection in the outcome of renal transplant patients with lymphoproliferative disorders. Ann Transplant, 2010; 15(2): 40-44
17. Snanoudj R, Durrbach A, Leblond V et al: Primary brain lymphomas after kidney transplantation: presentation and outcome. Transplantation, 2003; 76: 930-37
18. Schneck SA, Penn I: Cerebral neoplasms associated with renal transplantation. Arch Neurol, 1970; 22: 226-33
19. Cavaliere R, Petroni G, Lopes MB, Schiff D; International Primary Central Nervous System Lymphoma Collaborative Group: Primary central nervous system post-transplantation lymphoproliferative disorder: an International Primary Central Nervous System Lymphoma Collaborative Group Report. Cancer, 2010; 116(4): 863-70
20. Mamzer-Bruneel MF, Lomé C, Morelon E et al: Durable remission after aggressive chemotherapy for very late post-kidney transplant lymphoproliferation: A report of 16 cases observed in a single center. J Clin Oncol, 2000; 18(21): 3622-32
21. Hanto DW, Gajl-Peczalska KJ, Frizzera G et al: Epstein- Barr virus (EBV) induced polyclonal and monoclonal B-cell lymphoproliferative diseases occurring after renal transplantation. Ann Surg, 1983; 198: 356-69
22. Hachem RR, Chakinala MM, Yusen RD et al: Abdominal- pelvic lymphoproliferative disease after lung transplantation: presentation and outcome. Transplantation, 2004; 77(3): 431-37
23. Poirel HA, Bernheim A, Schneider A: Characteristic Pattern of Chromosomal Imbalances in Posttransplantation Lymphoproliferative Disorders: Correlation with Histopathological Subcategories and EBV Status. Transplantation, 2005; 80(2): 176-84
24. Paraskevas S, Coad JE, Gruessner A et al: Posttransplant Lymphoproliferative Disorder in Pancreas Transplantation: A Single-Center Experience. Transplantation, 2005; 80(5): 613-22
25. Muti G, Cantoni S, Oreste P et al: Post-transplant lympoproliferative disorders: improved outcome after clinico-pathologically tailored treatment. Haematologica, 2002; 87: 67-77
26. Phan TG, O'Neill BP, Kurtin PJ: Posttransplant primary CNS lymphoma. Neuro Oncol, 2000; 2(4): 229-38
27. Neuwelt EA, Frenkel EP, Gumerlock MK et al: Developments in the diagnosis and treatment of primary CNS lymphoma. A prospective series. Cancer, 1986; 58(8): 1609-20
28. Collins MH, Montone KT, Leahey AM et al: Posttransplant lymphoproliferative disease in children. Pediatr Transplant, 2001; 5: 250-57
29. Lok C, Viseux V, Denoeux JP, Bagot M: Post-transplant cutaneous T-cell lymphomas. Crit Rev Oncol Hematol, 2005; 56(1): 137-45
30. Peraira JR, Segovia J, Fuertes B et al: Current induction immunosuppression and post-heart transplant lymphoproliferative disorders. Transplant Proc, 2003; 35(5): 2009-10
31. Niedobitek G, Mutimer DJ, Williams A et al: Epstein- Barr virus infection and malignant lymphomas in liver transplant recipients. Int J Cancer, 1997; 73(4): 514-20
32. Abe T, Ichimaru N, Kokado Y et al: Post-transplant lymphoproliferative disorder following renal transplantation: a single-center experience over 40 years. Int J Urol, 2010; 17(1): 48-54
33. Pascual J: Post-transplant lymphoproliferative disorder - the potential of proliferation signal inhibitors. Nephrol Dial Transplant, 2007; 22(Suppl.1): i27-35
34. Morrison VA, Dunn DL, Manivel JC et al: Clinical characteristics of post-transplant lymphoproliferative disorders. Am J Med, 1994, 97: 14-24
35. Patel H, Vogl DT, Aqui N et al: Posttransplant lymphoproliferative disorder in adult liver transplant recipients: a report of seventeen cases. Leuk Lymphoma, 2007; 48(5): 885-91
36. Luo Y, Zhang AB, Huang H, Zheng SS: Is hepatitis B virus reactivation a risk factor in the development of posttransplant lymphoproliferative disorder following liver transplantation? Chin Med J (Engl), 2008; 121(13): 1237-40
37. Benkerrou M, Durandy A, Fischer A: Therapy for transplant-related lymphoproliferative disease. Hematol Oncol Clin North Am, 1993; 7: 467-75
38. Izadi M, Fazel M, Saadat SH, Taheri S: Hepatic involvement by lymphoproliferative disorders post liver transplantation: PTLD.Int. Survey. Hepatol Int, 2011; 5(3): 759-66
39. Buell JF, Gross TG, Hanaway MJ et al: Post-transplant lymphoproliferative disorder: significance of central nervous system involvement. Transplant Proc, 2005; 37: 954-55
40. Faye A, Quartier P, Reguerre Y et al: Chimaeric anti-CD20 monoclonal antibody (rituximab) in post-transplant B-lymphoproliferative disorder following stem cell transplantation in children. Br J Haematol, 2001; 115(1): 112-18
41. Choquet S, Leblond V, Herbrecht R et al: Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study. Blood, 2006; 107: 3053-57
42. Gonzalez-Barca E, Domingo-Domenech E, Capote FJ et al: Prospective phase II trial of extended treatment with rituximab in patients with B-cell posttransplant lymphoproliferative disease. Haematologica, 2007; 92: 1489-94
43. Komrokji RS, Oliva JL, Zand M et al: Mini-BEAM and autologous hematopoietic stem-cell transplant for treatment of post-transplant lymphoproliferative disorders. Am J Hematol, 2005; 79(3): 211-15
44. Shah GD, Yahalom J, Correa DD et al: Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma. J Clin Oncol, 2007; 25: 4730-35
45. Ruhstaller TW, Amsler U, Cerny T: Rituximab: active treatment of central nervous system involvement by non-Hodgkin's lymphoma? Ann Oncol, 2000; 11: 374-75
46. Traum AZ, Rodig NM, Pilichowska ME, Somers MJ: Central nervous system lymphoproliferative disorder in pediatric kidney transplant recipients. Pediatr Transplant, 2006; 10: 505-12
47. Cavaliere R, Petroni G, Lopes MB, Schiff D; International Primary Central Nervous System Lymphoma Collaborative Group: Primary central nervous system post-transplantation lymphoproliferative disorder: an International Primary Central Nervous System Lymphoma Collaborative Group Report. Cancer, 2010; 116(4): 863-70
48. Swinnen LJ, Mullen GM, Carr TJ et al: Aggressive treatment for postcardiac transplant lymphoproliferation. Blood, 1995; 86(9): 3333-40
49. Jacomet C, Girard PM, Lebrette MG et al: Intravenous methotrexate for primary central nervous system non-Hodgkin's lymphoma in AIDS. AIDS, 1997; 11: 1725-30
50. Taj MM, Messahel B, Mycroft J et al: Efficacy and tolerability of high-dose methotrexate in central nervous system positive or relapsed lymphoproliferative disease following liver transplant in children. Br J Haematol, 2008; 140: 191-96
51. Davis CL, Wood BL, Sabath DE et al: Interferonalpha treatment of posttransplant lymphoproliferative disorder in recipients of solid organ transplants. Transplantation, 1998; 66(12): 1770-79
52. Corn BW, Donahue BR, Rosenstock JG et al: Palliation of AIDS-related primary lymphoma of the brain: observations from a multi-institutional database. Int J Radiat Oncol Biol Phys, 1997; 38: 601-5
53. Helle TL, Britt RH, Colby TV: Primary lymphoma of the central nervous system. J Neurosurg, 1984; 60: 94-103
54. Berry MP, Simpson WJ: Radiation therapy in the management of primary malignant lymphoma of the brain. Int J Radiat Oncol Biol Phys, 1981; 7: 55-59
55. Littman P, Wang CC: Reticulum cell sarcoma of the brain. Cancer, 1975; 35: 1412-20
56. Woodman R, Shin K, Pineo G: Primary non-Hodgkin's lymphoma of the brain: A review. Medicine (Baltimore), 1985; 64(6): 425-30
57. Gonzalez DG, Schuster-Uitterhoeve AU: Primary non-Hodgkin's lymphoma of the central nervous system. Cancer, 1983; 5(1): 2048-52s